Real-world evidence (RWE) is increasingly shifting from a regulatory buzzword to operational reality at FDA. Over the past few years, the agency has made clear – through guidance, policy announcements, and leadership remarks – that it expects sponsors to incorporate real-world data (RWD) more strategically across the product lifecycle, while also sharpening expectations around data quality, transparency, and analytical rigor.

One of the most notable developments in late 2025 was FDA's decision to lower structural barriers to the use of RWE in regulatory submissions. In a widely-cited press announcement, FDA stated that it would accept RWE derived from de-identified data sources without requiring access to individual patient-level datasets for certain medical device submissions, and signaled that similar approaches are under active consideration for drugs and biologics. This shift reflects FDA's growing comfort with large-scale registries, claims databases, and electronic health records, provided that sponsors can demonstrate that the data are fit for purpose and methodologically sound.

At the same time, FDA has emphasized that greater flexibility does not mean lower standards. Updated guidance on the use of RWE for medical devices, along with ongoing discussions from center leadership, reinforce a consistent theme: sponsors bear the burden of showing data relevance, completeness, and appropriate control of bias. FDA has also continued to encourage early engagement, particularly through structured programs such as the Advancing RWE Program for drugs and biologics, which allows sponsors to align with reviewers on study design and analytical approaches before significant resources are committed.

Across public statements, FDA leadership has framed RWE as a complement – not a replacement – to traditional clinical evidence. The agency has highlighted RWE's value in supporting external control arms, informing label expansions, and addressing post market questions, while cautioning against overreliance on retrospective or poorly curated datasets.

Looking ahead to 2026, sponsors should expect RWE to play an increasingly central role in regulatory strategy, but with continued scrutiny on governance, data provenance, and statistical validity. For in-house legal and regulatory teams, success will depend on early planning, cross-functional coordination, and clear documentation of how real-world evidence meets FDA's evolving expectations.